 It is now my pleasure to turn the call over to Matt McLaughlin, Chief Financial Officer. Good morning and thank you for joining us to review Oxford Immunotecs financial results for the second quarter of 2020. Any statements made during this call that are not statements of historical or current facts are intended to be forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 